

# PROTIDES OF THE BIOLOGICAL FLUIDS

PROCEEDINGS OF THE TWENTY-THIRD COLLOQUIUM  
BRUGGE, 1975

*Edited by*

H. PEETERS

*Director of the Simon Stevin Institute and of the  
Laboratory of St. Jan's Hospital, Brugge (Belgium)*



PERGAMON PRESS  
OXFORD · NEW YORK · TORONTO  
SYDNEY · PARIS · FRANKFURT

U. K.	Pergamon Press Ltd., Headington Hill Hall, Oxford OX3 0BW, England
U. S. A.	Pergamon Press Inc., Maxwell House, Fairview Park, Elmsford, New York 10523, U.S.A.
CANADA	Pergamon of Canada, Ltd., P.O. Box 9600, Don Mills M3C 2T9, Ontario, Canada
AUSTRALIA	Pergamon Press (Aust.) Pty. Ltd., 19a Boundary Street, Rushcutters Bay, N.S.W. 2011, Australia
FRANCE	Pergamon Press SARL, 24 rue des Ecoles, 75240 Paris, Cedex 05, France
WEST GERMANY	Pergamon Press GmbH, 6242, Kronberg-Taunus, Pferdstrasse 1, Frankfurt-am-Main, West Germany

---

Copyright © 1976 Pergamon Press Ltd.

*All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of Pergamon Press Ltd.*

First edition 1976

Library of Congress Catalog Card No. 58-5908



*Printed in Great Britain by A. Wheaton & Co. Exeter*

0 08 019929 1 Y

0 08 019930 5 R

## *Contents*

PREFACE	xvii
ACKNOWLEDGEMENTS	xviii
<b>THE FOURTH ARNE TISELIUS MEMORIAL LECTURE</b> Carcinofetal Proteins HIDEMATSU HIRAI	3
<b>SECTION A. PROTEINASE INHIBITORS</b>	
<b>A1. Proteinase Inhibitor Interaction</b>	
<b>A1.1. Molecular Aspects and Quantitation</b>	
Chemical Studies on Proteinase Inhibition E. T. KAISER, J. SUH and T.-W. CHAN	27
Mechanism and Structure of Human Alpha-1-Proteinase Inhibitor DAVID A. JOHNSON and JAMES TRAVIS	35
Inhibition of Urokinase by Purified Human $\alpha_1$ -Antitrypsin I. CLEMMENSEN and F. CHRISTENSEN	39
Interaction between Alpha <sub>1</sub> -Antitrypsin and Alpha <sub>2</sub> -Macroglobulin in the Elimination of Proteolytic Enzymes KJELL OHLSSON	43
Some Properties of a Complex between $\alpha_2$ -Macroglobulin and Brinase HANS KIESSLING	47
Kunitz Bovine Trypsin Inhibitor: Interaction with $\alpha$ -Chymotrypsin JACQUELINE CHAUVET and ROGER ACHER	53
Kinetics of the Interaction of Virgin and Modified Bovine Trypsin Kallikrein Inhibitor (Kunitz) with $\beta$ -Trypsin U. QUAST, J. ENGEL, G. MAIR and H. TSCHESCHE	57
Interaction of Proteinase Inhibitors with Blastocyst Proteinases involved in Implan- tation H. W. DENKER	63

Blocking of C $\bar{1}$ Esterase Inhibitor by Cold Promoted Activation of Factor VII E. A. VAN ROYEN, W. KEMPES-VAN LEEUWEN, M. VOSS and K. W. POND- MAN	69
Direct Identification of Specific Protease Inhibitors in Mixtures by Modified Quantitative Immunoelectrophoresis J. RAMLAU, O. J. BJERRUM and T. C. BØG-HANSEN	73
Studies on the Inhibition of Renin by Radioimmunoassay M. EID, S. SCHARPÉ and A. LAUWERS	79
<b>A1.2. Kinetics and Thermodynamics</b>	
Thermodynamics and Kinetics of the Interaction of Trypsin with Trypsin Inhibitors M. LASKOWSKI JR., W. R. FINKENSTADT, J. A. MATTIS and R. E. McKEE	85
The Inhibition of Human and Bovine Trypsins and Chymotrypsins by the Inter- $\alpha$ - Inhibitor from Human Plasma J. BIETH and M. AUBRY	93
Kinetic and Thermodynamic Studies of Human Alpha-1-Proteinase Inhibitor J. SAKLATVALA and G. C. WOOD	99
<b>A2. Structure and Function of Human Proteinase Inhibitors</b>	
<b>A2.1. In Plasma</b>	
Structure of $\alpha_1$ -Antitrypsins J. O. JEPSSON and C. B. LAURELL	103
$\alpha$ -1-Proteinase Inhibitor Deficiency Disease: A Probable Inborn Error of Carbohydrate Side Chain Synthesis JAMES TRAVIS and RALPH PANNELL	109
New Data Concerning Inter-Alpha-Trypsin-Inhibitor M. STEINBUCH, R. AUDRAN, P. LAMBIN and J. M. FINE	115
The Role of Sialic Acid in Hepatic Uptake of Alpha $_1$ -Antitrypsin JOSHUA A. FIERER, PHYLLIS SAMPSON and INES MANDL	119
Preparative Separation of Various Bands of Alpha-1-Antitrypsin by Electrofocusing in Thin-layer Polyacrylamide Gel J. LEBAS, A. HAYEM and G. BISERTE	125
Circular Dichroism Studies on $\alpha$ -1-Proteinase Inhibitor G. C. WOOD, D. D. WHITE and J. SAKLATVALA	129

Subunit Structure of Human Alpha-2-Macroglobulin. Its Relationships with its Biological Activity	133
M. STEINBUCH, R. AUDRAN, P. LAMBIN and J. M. FINE	
Comparative Study of Rat $\alpha_1$ -Macroglobulin and Rat $\alpha_2$ -Macroglobulin: Interaction with Trypsin and Chymotrypsin	139
F. GAUTHIER and H. MOURAY	
Primary Structure of Hirudin, A Thrombin-Specific Inhibitor	145
TORBEN E. PETERSEN, HAROLD R. ROBERTS, LARS SOTTRUP-JENSEN, STAFFAN MAGNUSSON and D. BAGDY	
The Partial Purification and Characterization of Inter- $\alpha$ -Antiplasmin from Human Serum	151
M. J. GALLIMORE	
A Low Molecular Weight Elastase Inhibitor from Human Serum	157
JOHN MANAHAN and INES MANDL	
<b>A2.2. In the Reproductive System</b>	
Acid-stable Proteinase Inhibitors from Human Seminal Plasma: Purification and Characterization	163
HANS SCHIESSLER, MARIANNE ARNHOLD and HANS FRITZ	
Proteinase Inhibitors in Testicular and Epididymal Fluid	171
J. J. O. SUOMINEN and B. P. SETCHELL	
An Acid-stable Proteinase Inhibitor in Human Cervical Mucus	177
OTTO WALLNER, HANS FRITZ and KARL HOCHSTRASSER	
<b>A2.3. In Pancreatic Tissue</b>	
Human Pancreatic Secretory Trypsin Inhibitor, Amino Acid Sequence	183
LEWIS J. GREENE and DIANA C. BARTELT	
$^1\text{H}$ NMR Studies of the Dynamics of the Solution Conformation of the Basic Pancreatic Trypsin Inhibitor (BPTI)	189
G. WAGNER and K. WÜTHRICH	
The Effect of Trypsin-inhibitors on the Rat Exocrine Pancreas	195
U. R. FOLSCH, K. WINCKLER and K. C. WORMSLEY	
Comparative $^1\text{H}$ NMR Studies of the Solution Conformation of the Cow Colostrum Trypsin Inhibitor (CTI), The Trypsin Inhibitor of <i>Helix Pomatia</i> (HPI) and the Basic Pancreatic Trypsin Inhibitor (BPTI)	201
K. WÜTHRICH, G. WAGNER and H. TSCHESCHE	

Isolation and Properties of an Aortic Elastase W. HORNEBECK and L. ROBERT	205
Measurement of the Proteinase Inhibitors of the Bovine Pancreas by Radio-immunoassay E. FINK and L. J. GREENE	211
<b>A2.4. In Other Tissues</b>	
Tissue Inhibitors are Cell Growth Regulators REUBEN EISENSTEIN, KLAUS E. KUETTNER, LAWRENCE W. SOBLE and NINO SORGENTE	217
The Possible Role of Protease Inhibitors in Cartilage Metabolism KLAUS E. KUETTNER, LAWRENCE W. SOBLE, NINO SORGENTE and REUBEN EISENSTEIN	221
The Isolation, Purification and Partial Characterization of Proteinase Inhibitors from Bovine Cartilage and Aorta NINO SORGENTE, KLAUS E. KUETTNER and REUBEN EISENSTEIN	227
Characterization of Proteinase-Inhibitor Complexes in the Purulent Secretions of Mucous Membranes as Complexes between Leucocytic Elastase and Proteinase Inhibitors K. HOCHSTRASSER and K. SCHORN	231
<b>A3. Structure and Function of Animal Proteinase Inhibitors</b>	
Evolution of Proteinase Inhibitors I. KATO, J. SCHRODE, K. A. WILSON and M. LASKOWSKI, Jr.	235
Electrophoretic Variants of Serum $\alpha_1$ -Antitrypsin in Baboons J. P. MARTIN, R. SESBOUE and C. ROPARTZ	245
Antitrypsin Polymorphism in Sub-human Primates JOHN A. PIERCE	249
Structure, Biochemistry and Comparative Aspects of Mammalian Seminal Plasma Acrosin Inhibitors H. TSCHESCHE, S. KUPFER, R. KLAUSER, E. FINK and H. FRITZ	255
About the Aminoacid Sequence of the Proteinase Inhibitors from Dog Submandibular Glands K. HOCHSTRASSER, G. BRETZEL and E. WACHTER	267
Characterization and Inhibitory Properties of Snail Secretory Proteinase Inhibitors T. DIETL and H. TSCHESCHE	271

Interaction of Exopeptidases with Specific Proteins from <i>Ascaris Lumbricoides</i> G. A. HOMANDBERG and R. J. PEANASKY	279
Broad Specificity Proteinase Inhibitors from Sea Anemones G. WUNDERER, L. BERESS, W. MACHLEIDT and H. FRITZ	285

## SECTION B. CLINICAL EVALUATION OF PLASMA PROTEIN PATTERNS

### B1. Techniques and Methods

An Automated Approach to the Preparation of Plasma Protein Profiles LAWRENCE M. KILLINGSWORTH	291
Determination of Proteins by Laser Nephelometry A. SIEBER and J. GROSS	295
Immunochemical Determination of Blood Proteins MOGENS BLOM and NIELS HJORNE	299
A New Radioimmunoassay of $\alpha$ -Fetoprotein and Carcinoembryonic Antigen SHINZO NISHI and HIDEMATSU HIRAI	303

### B2. Interpretation

Human Plasma Proteins Discovered During the Last Few Years and Their possible Value for Clinical Diagnosis H. G. SCHWICK	309
The Management of Specific Protein Data ROBERT F. RITCHIE	317
Routine Serum Protein Analysis: Trends, Facts and Fallacies J. KOHN	325
The Use of Discriminant Function Analysis in Selecting Individual Proteins for Routine Clinical Investigation K. McPHERSON and H. G. MINCHIN CLARKE	333
$\alpha_2$ -Antithrombin Levels in Relation to Age and Sex A. MILFORD WARD	339
The Serum Level of $\beta_2$ -Microglobulin ( $\beta_2\mu$ ) – A Low Molecular Weight Protein LARS WIBELL and F. ANDERS KARLSSON	343

**B3. Pregnancy Levels**

- Plasma Protein Profiles of Serum and Amniotic Fluid in Normal Pregnancy and Pre-eclampsia 349  
D. BURNETT, S. M. WOOD and A. R. BRADWELL
- $\alpha_1$ -fetoprotein in Pregnancy 353  
A. MILFORD WARD, C. R. STEWART and J. WATKINS

**B4. Profiles Typical of a Disorder****B4.1. Alpha-antitrypsin System**

- Purification of  $\alpha_1$ -Antitrypsin Utilizing Thiol-Disulphide Interchange 359  
CARL-BERTIL LAURELL
- Prevalence of Pi Types among Newborns of Different Ethnic Backgrounds 363  
H. EVANS, N. FORMAINI and I. MANDL
- The Alpha<sub>1</sub>-Antitrypsin Null Gene Frequency 367  
GILLIAN BLUNDELL, R. B. COLE and N. C. NEVIN
- Pi M<sub>Rouen</sub> Phenotype in a Pi- subject 371  
J. P. MARTIN, R. SESBOUE and C. ROPARTZ
- A New Deficiency Allele of Alpha<sub>1</sub>-Antitrypsin: Pi M<sub>Malton</sub> 375  
D. W. COX
- Proteinase Inhibitors in Bronchial Secretions from Patients with Alpha-1-Antitrypsin Deficiency 379  
A. LAINE, J. LEBAS and A. HAYEM
- Alpha-1-Antitrypsin Deficiency and Adult Liver Disease 383  
E. D. JANUS and R. W. CARRELL
- High Serum Complement Component Levels in Patients with Alpha-1-Antitrypsin Deficiency 387  
Ph. ARNAUD, R. CREYSSEL, F. C. BERTHOUX, C. CHAPUIS-CELLIER and A. M. FREYRIA
- B4.2. Immune Disorders**
- Immunoglobulin Abnormalities in Primary Immunodeficiency Diseases 395  
TADASHI KAWAI



Immune System Disorders in Man and in Experimental Models accompanied by the Production of Homogeneous Immunoglobulins – Paraproteins J. RADL	405
A New Case of IgE Myelomatosis R. J. MILLS, M. N. FAHIE-WILSON, P. M. CARTER, A. EZEOKÉ and J. R. HOBBS	409
Imbalances of K/λ Immunoglobulin Light Chain Ratios in Normal Individuals and in Immunodeficient Patients F. SKVARIL, S. BARANDUN, A. MORELL, F. KUFFER and MARIANNE PROBST	415
On the Idiotypic Determinants of Human Paraproteins: A Family Study TH. OCKHUIZEN, J. J. M. FESTEN, E. H. DE WAARD-KUIPER, J. MARRINK and E. MANDEMA	421
<b>B4.3. Liver and Renal Diseases</b>	
Changes of the Dye-binding Properties of Serum Proteins in Liver Diseases KOICHI KANAI, NAOMI TANAKA, TOSHITSUGU ODA and MIKIKO SAKAZAKI	427
Plasma Protein Pattern in Hepatitis A and B C.-O. KINDMARK	431
Serum and Urinary Protein Analysis by SDS–PAA Electrophoresis Combined with Immunoprecipitation: Dimer Albumin in the Nephrotic Syndrome WOLF H. BOESKEN and EDMUND NOLLER	437
Behaviour of Prealbumin, Albumin, Cholinesterase and Normotest in Blood of Patients with Chronic Hepatitis and Postnecrotic Cirrhosis A. AGOSTONI, E. DEL NINNO, B. MARASINI, M. COLOMBO and R. STABILINI	441
The Level of Acid Stable Protease Inhibitors in Plasma as an Indicator of Renal Function H. FEUTH, B. M. KEMKES and K. HOCHSTRASSER	445
<b>B4.4. Rheumatic Diseases</b>	
Changes in Concentration and Synthesis Rates of Plasma Proteins during Experimental Arthritis M. E. J. BILLINGHAM and A. H. GORDON	451
Serum Protein Profiles in Rheumatoid Arthritis J. WATKINS, A. MILFORD WARD, P. A. E. WHITE and A. J. SWANNELL	455

**B5. Factors Regulating Protein Profiles**

The Definitive Role of Known Hormones in the Regulation of Net Biosynthesis of Five Acute Phase Plasma Proteins (APPP) by the Isolated Perfused Rat Liver: Corticosterone LEON L. MILLER	461
How is C-Reactive Protein (CRP) Synthesis Regulated? Studies in Isolated Perfused Rabbit Liver IRVING KUSHNER, WILLIAM N. RIBICH and JAMES B. BLAIR	471
$\alpha_2$ -Macroglobulin as an <i>in vivo</i> tracer K.-L. WONG and E. REGOECZI	475
Protein Permeability of the Blood – CSF Barrier K. FELGENHAUER, G. SCHLIEP and N. RAPIC	481
The Blood – CSF Barrier for IgG: A Semiological Estimation in Multiple Sclerosis BERTRAND DELPECH and JACQUES BOQUET	489

**SECTION C. AFFINITY CHROMATOGRAPHY****C1. Biospecific Chromatography****C1.1. Matrices and Ligands**

Improved Agarose Matrixes for Biospecific Affinity Chromatography TORGNY LAAS	495
Photo-beads and Oxirane Beads as Solid Supports for Catalysis and Biospecific Adsorption D. M. KRAMER, K. LEHMANN, H. PENNEWISS and H. PLAINER	505
Some Microscopic Observations on Matrix Structure in Affinity Chromatography P. J. NEAME, S. G. DOLEY, M. J. HARVEY and P. D. G. DEAN	513
Preparation of Adsorbents for Biospecific Affinity Chromatography LARS SUNDBERG and JERKER PORATH	517
Stability of the Binding Groups generated by CNBr Activation of Agarose MARIUS JOUSTRA and ROLF AXÉN	525
Coupling of Ligands to Crosslinked Sepharose® in Organic Solvents JAN ROSENGREN and MAGNUS GLAD	531

Enzyme Immobilization and Covalent Chromatography by means of Thiol–Disulphide Exchange JAN CARLSSON	537
<b>C1.2. Coupled Molecules</b>	
Affinity Chromatography on Polylysine-Sepharose 4B BEATRICE KASSELL, CHRISTINE L. WRIGHT and PETER H. WARD	541
The Effect of Heparin on the Affinity Chromatography of Human Plasminogen M. W. C. HATTON and E. REGOECZI	545
Affinity Chromatography of the Subunits of Human C $\bar{I}$ DAVID H. BING, JUDITH M. ANDREWS, F. L. SUDDATH and ROD SPENCER	551
Application of Immuno-affinity Chromatography to the Removal of Contaminants and to the Ultimate Purification of a Glycoprotein J. FEGER, D. BIOU, G. DURAND and J. AGNERAY	559
Separation of Oncofoetal Proteins by Affinity Chromatography M. PAGE	565
Affinity Chromatography of Lactoferrin on Immobilized Ferritin J. J. PAHUD and H. HILPERT	571
Studies of Plasmamembrane Surface Proteins from Human Kidney by Con A Affinity Chromatography J. E. SCHERBERICH and A. W. MONDORF	575
Affinity Chromatography of Lipoproteins with Heparin-Agarose H. U. KLÖR, J. W. SCHMIDT, H. DITSCHUNEIT and J. GLOMSET	581
Cancer Immunity. Polymerized Autologous Tumour Tissue in Cancer-Immunotherapy T. TALLBERG, H. TYKKA, M. TURUNEN, K. J. ORAVISTO, T. RYTOMAA, O. CARLSON, H. STRANDSTROM, K. MAHLBERG and S. SARNA	589
The Purification of Antigens and Antibodies K. B. COOKE, PARUL HAZARIKA and CLAIRE BENNETT	599
Scaling up Immunoaffinity Chromatography by Automation WESSEL VAN DER LOO and RAYMOND HAMERS	603
Automatic Separation of Mouse Serum IgG1 and IgG2 using Immobilized Specific anti-H-chain Antibodies G. J. VAN KAMP, W. P. M. TAMBOER, J. L. J. JANSEN, R. A. P. KOENE and P. G. A. B. WIJDEVELD	609

Affinity Chromatography of Antigens from <i>Candida Albicans</i> H. E. CARLSSON and S. BERNANDER	613
Affinity Chromatography with Glycocholic Acid as Ligand: purification of 3 $\alpha$ -Hydroxysteroid Dehydrogenase (E.C.1.1.1.50, 3 $\alpha$ -HSD) from <i>Pseudomonas Testosteroni</i> LARS AUKRUST	617
Affinity Chromatography of Calf Intestine Alkaline Phosphatase O. BRENNNA, M. PERRELLA, M. PAGE and P. G. PIETTA	623
Bioaffinity Chromatography of Stem Bromelain and its Interaction with Human $\alpha$ 1-Antitrypsin W. M. COOREMAN, S. SCHARPÉ and A. LAUWERS	627
Immobilization of Rat Liver Arginase GRAZYNA MUSZYNSKA	633
Affinity Adsorbents for Dehydrogenases A. H. ROEDER	639
Affinity Electrophoresis of Phosphorylases and $\alpha$ -Amylases K. TAKEO, A. KUWAHARA, H. NAKAYAMA and S. NAKAMURA	645
The Use of Affinity Chromatography for the Subfractionation of Polyadenylated RNA on Oligo(dT)-Cellulose L. GYENES and P. K. GANGULI	651
Interaction between Lysosomal Glycosidases from Human Plasma and Lectins J. A. KINT	659
Virus Purification by <i>Vicia ervilia</i> Lectin Coupled to Sepharose TORE KRISTIENSEN	663
<b>C2. Hydrophobic Interaction Chromatography</b>	
Purification of Proteins by Hydrophobic Interaction Chromatography STELLAN HJERTÉN	667
Basic Properties of Hydrophobic Agaroses H. P. JENNISSSEN	675
Hydrophobic Separation of Plasma Proteins and Lipoproteins H. PEETERS, V. BLATON and H. CASTER	681

CONTENTS

xv

Hydrophobic Chromatography of Catalases and Hemoglobins on a Series of Alkyl-substituted Sepharoses M. BREITENBACH	687
The Geometrical Chromatography Model proven by Pore Radius Determinations in Porous Glasses H. WALDMANN-MEYER	691
AUTHOR INDEX	695
SUBJECT INDEX	697

## Measurement of the Proteinase Inhibitors of the Bovine Pancreas by Radioimmunoassay\*

E. FINK† and L. J. GREENE††

BOVINE pancreas contains two different polypeptide trypsin inhibitors, Kunitz inhibitor<sup>(6,8)</sup> and Kazal inhibitor.<sup>(3,7)</sup> Some of their properties are summarized in Table 1. Both inhibitors are found in the bovine pancreatic tissue in approximately equimolar concentrations,<sup>(2)</sup> yet only the Kazal inhibitor is detectable in pancreatic juice.

As the first step in the study of the physiological role of these two polypeptide inhibitors we have set up a radioimmunoassay for each inhibitor, because this analytical method provides both specificity and high sensitivity. In this communication we describe the labelling of Kazal and Kunitz inhibitors with <sup>125</sup>I using the lactoperoxidase method,<sup>(9,12)</sup> present a radioimmunoassay for each inhibitor and report the application of the assays in an *in vitro* secretion study of bovine pancreas.

TABLE 1. BOVINE PANCREATIC TRYPSIN INHIBITORS

	Kazal	Kunitz
Trypsin inhibition	+	+
Acrosin inhibition	+	+
Plasmin inhibition	—	+
Chymotrypsin inhibition	—	+
Kallikrein inhibition	—	+
Amino acids/molecule	56	58
Molecular weight	6161	6518
Isoelectric point	4.8, 5.2, 5.9	10.5
Present in:		
pancreatic tissue	+ (~1.5X)	+ (~1X)
pancreatic juice	+	—

### RADIOIODINATION

The procedure described by Thorell and Johansson for the iodination of polypeptide hormones using lactoperoxidase<sup>(12)</sup> was employed for the <sup>125</sup>I-labelling of Kunitz and Kazal inhibitors.<sup>(1)</sup> Iodination and purification procedures were identical for both inhibitors. Table 2 presents the experimental conditions by which the incorporation of 0.4 nmole <sup>125</sup>I per

\*Research carried out at Brookhaven National Laboratory under the auspices of the U.S. Atomic Energy Commission.

†Visiting Biochemist at Brookhaven National Laboratory, 1972–1974. Supported by Deutsche Forschungsgemeinschaft. Present address: Institut für Klinische Chemie und Klinische Biochemie der Universität München, D-8 München 2, Nussbaumstr. 20, Germany.

††Brookhaven National Laboratory, Upton, N.Y. 11973, USA.

TABLE 2. ENZYMATIC IODINATION OF BOVINE PANCREATIC TRYPSIN INHIBITORS

(a)	Na <sup>125</sup> I, 1 mCi, pH 8–10	10 $\mu$ l
(b)	Potassium phosphate buffer, 0.4 M, pH 6.1	10 $\mu$ l
(c)	Inhibitor, 4 $\mu$ g in H <sub>2</sub> O	5 $\mu$ l
(d)	Lactoperoxidase (Calbiochem) 1 $\mu$ g in H <sub>2</sub> O	4 $\mu$ l
(e)	H <sub>2</sub> O <sub>2</sub> , 1 $\mu$ g in five 2 $\mu$ l additions at 30 min intervals	10 $\mu$ l
(f)	Reaction stopped after 2.5 hr by addition of 20 $\mu$ l NaN <sub>3</sub> (0.3%), 200 $\mu$ l NaI (0.1%) and 600 $\mu$ l G-50 elution buffer	




FIG. 1. Isolation of <sup>125</sup>I-Kazal inhibitor by gel filtration. The reaction mixture was applied to a Sephadex G-50 fine column, 0.6 × 120 cm, equilibrated and developed at 4°C with 0.05 M Tris-HCl buffer, pH 8.6, containing 0.5% bovine serum albumin, 0.5 M KCl and 0.02% NaN<sub>3</sub>. The numbers indicate the percentage of recovered radioactivity in each effluent peak.

1 nmole inhibitor was achieved. The number of iodine atoms incorporated per molecule inhibitor can be controlled by altering the amount of inhibitor in the reaction mixture while keeping all other parameters unchanged.

The reaction mixture was immediately subjected to gel filtration on Sephadex G-50 fine (Fig. 1). The iodinated inhibitor was eluted as a symmetrical peak in fractions 27–33, the same volume in which unlabeled inhibitor was eluted. The gel filtration step effectively separated the radioactive inhibitor from high molecular weight iodinated material (fractions 16–25), presumably derived from the lactoperoxidase preparation, and from low molecular weight radioactive material (fractions 41–46), which is probably free <sup>125</sup>I. Iodinated Kunitz and Kazal inhibitor preparations were stored at 4°C in the Sephadex G-50 elution buffer. They were generally rechromatographed on Sephadex G-50 prior to a radioimmunoassay experiment. Upon rechromatography most of the iodinated material was eluted in the position of the inhibitor, a small amount of the radioactivity appeared in the low molecular weight region. The preparations were generally retained for up to eight weeks for use in radioimmunoassay.




FIG. 2. Dose-response curve for the radioimmunoassay of Kazal inhibitor. Each tube contained 100  $\mu$ l  $^{125}$ I-inhibitor (25,000 cpm), 200  $\mu$ l standard diluent (SD: 0.05 M potassium phosphate buffer pH 7.6, 0.25% bovine serum albumin, 0.02%  $\text{NaN}_3$ ), 100  $\mu$ l unlabeled inhibitor dissolved in SD, 100  $\mu$ l of antiserum at a dilution sufficient to bind 50% of the labeled inhibitor. After 48 hr at 21°C the bound inhibitor was separated by the addition of 100  $\mu$ l goat antirabbit IgG serum (1:30) and 100  $\mu$ l rabbit serum (1:600) followed by incubation at 4°C for 12 hr. The radioactivity of the precipitate was counted after centrifugation.

#### RADIOIMMUNOASSAY PROCEDURE

Antiserum to Kunitz inhibitor was prepared from rabbits immunized with the antigen in incomplete Freund's adjuvant; antiserum to Kazal inhibitor was prepared from rabbits with Kazal inhibitor coupled to human albumin; both antisera were used without any further purification. The double antibody method was employed for the radioimmunoassays using goat antirabbit IgG serum as the second antibody to separate bound inhibitor from free inhibitor.<sup>(4)</sup>

Studies of the binding of labeled inhibitor showed that 85–90% of the radioactivity in each  $^{125}$ I inhibitor preparation was bound by the antibody. A standard curve for the radioimmunoassay of Kazal inhibitor is given in Fig. 2. Linearization of the dose-response curve was achieved for either antigen-antibody system by plotting the logit transform of the response versus log dose of antigen.<sup>(10,11)</sup> Both assays were sensitive to 0.04–0.08 ng inhibitor and were generally used in the range of 0.1–5 ng inhibitor per tube with deviations of replicates  $\pm 10\%$  or less. The experimental conditions for incubation and separation of bound antigen are given in the legend to Fig. 2. We have not attempted to increase the sensitivity of the assay, although it is probable that sensitivity could be increased by using inhibitor preparations of higher specific radioactivity. The system described here is reasonably stable and provides high sensitivity.

There is no cross-reactivity detectable between the Kunitz and the Kazal inhibitor-antiserum systems. Neither iodinated inhibitor is bound by the antiserum to the other inhibitor under the conditions of the double antibody radioimmunoassay. 800-fold molar excess of one inhibitor had no effect on the quantitative determination of the second inhibitor. Trypsin interfered with the assays of both inhibitors by reducing the amount of iodinated inhibitor bound to the antibody. This suggests that the inhibitor-trypsin complex is less effectively bound to the antibody than the inhibitor. For this reason, samples which might have contained






FIG. 3. Kinetics of release of amylase ( $\Delta$ — $\Delta$ ), and of Kazal ( $\circ$ — $\circ$ ) and Kunitz inhibitors ( $\bullet$ — $\bullet$ ) from bovine pancreatic slices in the presence (+ C) and absence (- C) of  $10^{-6}$  M carbamylcholine in the incubation medium.

trypsin were treated with 2.5% trichloroacetic acid (TCA) to precipitate the trypsin while the inhibitors remain in solution.<sup>(7,8)</sup> The recovery of each iodinated inhibitor added to the pancreatic juice or homogenates of pancreas was 70–80% after treatment with TCA.

#### IN VITRO SECRETION STUDY OF BOVINE PANCREAS

The RIAs of Kazal and Kunitz inhibitors were employed for the study of the secretion of bovine pancreas.<sup>(5)</sup> Slices of fresh bovine pancreatic tissue were placed in Krebs-Ringer buffer containing glucose and amino acids and washed repeatedly with the same solution. Two sets of slices were incubated in the Krebs-Ringer buffer at  $37^{\circ}\text{C}$ ; the medium of one set was  $10^{-6}$  M in carbamylcholine, a secretagogue which is a choline-esterase-resistant analog of acetylcholine. At the times shown in Fig. 3 (abscissa), aliquots of the incubation media were removed and replaced by fresh medium. After the incubation the tissue slices were homogenized in water. All samples and the homogenates were assayed for their concentration in amylase by a photometric method and for their concentrations in Kazal and Kunitz inhibitors by radioimmunoassay. Figure 3 shows the kinetics of release of the three substances.

Two facts confirm the secretory nature of Kazal inhibitor. First, the secretagogue carbamylcholine stimulates its release into the medium. Second, the kinetics of release of Kazal inhibitor into the medium is identical with those of amylase, whose secretory nature is well known.

The release of Kunitz inhibitor into the medium is completely different from that of Kazal inhibitor and is probably due to cell death. By contrast with Kazal inhibitor the release of Kunitz inhibitor is not stimulated significantly by carbamylcholine, nor does it parallel that of amylase, thus demonstrating the non-secretory nature of Kunitz inhibitor.

#### ACKNOWLEDGEMENTS

We wish to express our appreciation to Dr. Ernst Truscheit, Biochemical Laboratories, Bayer AG, for providing us with the Kunitz inhibitor (Trasylol) and antisera to the inhibitor. We are very grateful to Dr. James D. Jamieson, Section of Cell Biology, Yale University, who supplied us with Kazal inhibitor antisera and whose collaboration made the *in vitro* secretion studies possible.

#### REFERENCES

1. FINK, E. and GREENE, L. J., In *Proteinase Inhibitors* (Bayer Symposium V), *Proc. 2nd Int. Res. Conf.*, Grosse Ledder, 1973. FRITZ, H., TSCHESCHE, H., GREENE, L. J. and TRUSCHEIT, E. (eds.), p. 243. Springer Verlag, Berlin, 1974.
2. FRITZ, H., WOITINAS, F. and WERLE, E., *Z. Physiol. Chem.* 345, 168 (1966).
3. GUY, O., SHAPANKA, R. and GREENE, L. J., *J. Biol. Chem.* 246, 7740 (1971).
4. HUNTER, W. M. and GANGULI, P. C., In KIRKHAM, K. E. and HUNTER, W. M. (eds.), *Radioimmunoassay Methods*, p. 243. Edinburgh—London, Churchill Livingstone, 1971.
5. JAMIESON, J. D. and PALADE, G. E., *J. Cell. Biol.* 48, 503 (1971).
6. KASSEL, B. and LASKOWSKI, M., Sr., *Acta Biochim. Polon.* 13, 287 (1966).
7. KAZAL, L. A., SPICER, D. S. and BRAHINSKY, R. A., *J. Am. Chem. Soc.* 70, 3034 (1948).
8. KUNITZ, M. and NORTHROP, J. H., *J. Gen. Physiol.* 19, 911 (1936).
9. MARCHALONIS, J. J., *Biochem. J.* 113, 299 (1969).
10. RODBARD, D., BRIDSON, W. and RAYFORD, P. L., *J. Lab. Clin. Med.* 74, 770 (1969).
11. RODBARD, D., In ODELL, W. D. and DAUGHADAY, W. H. (eds.), *Principles of Competitive Protein-Binding Assays*, p. 204. Philadelphia, J. B. Lippincott Co., 1971.
12. THORELL, J. I. and JOHANSSON, B. G., *Biochim. Biophys. Acta (Amst.)* 251, 363 (1971).

A U T H O R   I N D E X

- Acher, R. 54  
 Agneray, J. 559  
 Agostoni, A. 441  
 Andrews, J.M. 551  
 Arnaud, Ph. 387  
 Arnhold, M. 163  
 Aubry, M. 93  
 Audran, R. 115, 133  
 Aukrust, L. 617  
 Axén, R. 525
- Bagdy, D. 145  
 Barandun, S. 415  
 Bartelt, D.C. 184  
 Bennett, C. 599  
 Béress, L. 285  
 Bernander, S. 613  
 Berthoux, F.C. 387  
 Bieth, J. 93  
 Billingham, M.E.J. 451  
 Bing, D.H. 551  
 Biou, D. 559  
 Biserte, G. 125  
 Bjerrum, O.J. 73  
 Blair, J.B. 471  
 Blaton, V. 681  
 Blom, M. 299  
 Blundell, G. 367  
 Boesken, W.H. 437  
 Bøgg-Hansen, T.C. 73  
 Boquet, J. 499  
 Bradwell, A.R. 349  
 Breitenbach, M. 687  
 Brenna, O. 623  
 Bretzel, G. 267  
 Burnett, D. 349
- Carlson, O. 589  
 Carlsson, H.E. 613  
 Carlsson, J. 537  
 Carrell, R.W. 383  
 Carter, P.M. 409  
 Caster, H. 681  
 Chan, T.W. 27  
 Chapuis-Cellier, C. 387  
 Chauvet, J. 54  
 Christensen, F. 40  
 Clemmensen, I. 40  
 Cole, R.B. 367
- Colombo, M. 441  
 Cooke, K.B. 599  
 Cooreman, W.M. 627  
 Cox, D.W. 375  
 Creyssel, R. 387
- Dean, P.D.G. 513  
 Del Nimo, E. 441  
 Delpech, B. 489  
 Denker, H.W. 63  
 De Waard-Kuiper, E.H. 421  
 Dietl, T. 271  
 Ditschuneit, H. 581  
 Doley, S.G. 513  
 Durand, G. 559
- Eid, M. 79  
 Eisenstein, R. 217,221, 227  
 Engel, J. 57  
 Evans, H. 363  
 Ezeoke, A. 409
- Fahie-Wilson, M.N. 409  
 Feger, J. 559  
 Felgenhauer, K. 481  
 Festen, J.J.M. 421  
 Feuth, H. 445  
 Fierer, J.A. 119  
 Fine, J.M. 115,133  
 Fink, E. 211  
 Finkenstadt, W.R. 86  
 Fölsch, U.R. 195  
 Formaini, N. 363  
 Freyria, A.M. 387  
 Fritz, H. 151,163,177,285
- Gallimore, M.J. 151  
 Ganguli, P.K. 651  
 Gauthier, F. 139  
 Glad, M. 531  
 Glomset, J. 581  
 Gordon, A.H. 451  
 Greene, L.J. 211,184  
 Gross, J. 295  
 Gyenes, L. 651
- Hamers, R. 603  
 Hatton, M.W.C. 545
- Hayem, A. 125, 379  
 Harvey, M.J. 513  
 Hazarika, P. 599  
 Hilpert, H. 571  
 Hirai, H. 4, 303  
 Hjertén, S. 667  
 Hjørne, N. 299  
 Homandberg, G.A. 279  
 Hornebeck, W. 206  
 Hobbs, J.R. 409  
 Hochstrasser, K. 267,231
- Jansen, J.L.J. 609  
 Janus, E.D. 383  
 Jennissen, H.P. 675  
 Jeppsson, J.O. 103  
 Johnson, D.A. 35  
 Joustra, M. 525
- Kaiser, E.T. 27  
 Kanai, K. 427  
 Karlsson, F.A. 343  
 Kassel, B. 541  
 Kato, I. 235  
 Kawai, T. 395  
 Kempes, W. 69  
 Kemkes, B.M. 455  
 Kiessling, H. 48  
 Killingsworth, L.M. 291  
 Kindmark, C.O. 431  
 Kint, J.A. 659  
 Klauser, R. 255  
 Klör, H.U. 581  
 Kohn, J. 325  
 Koene, R.A.P. 609  
 Krämer, D.M. 505  
 Kristiansen, T. 663  
 Kuettner, K.E. 217,221, 227  
 Kuffer, F. 425  
 Kupfer, S. 255  
 Kushner, I. 471  
 Kuwahara, A. 645
- Låås, T. 495  
 Laine, A. 379  
 Lambin, P. 115, 133  
 Laskowski, M. 86, 235  
 Laurell, C.B. 103,359

- Lauwers, A. 79,627  
 Lebas, J. 125,379  
 Lehmann, K. 505  
  
 Machleidt, W. 285  
 McKee, R.E. 86  
 McPherson, K. 333  
 Magnussen, S. 145  
 Mahlberg, K. 589  
 Mair, G. 57  
 Manahan, J. 157  
 Mandema, E. 421  
 Mandl, I. 119, 157, 363  
 Marasini, B. 441  
 Marrink, J. 421  
 Martin, J.P. 245,371  
 Mattis, J.A. 86  
 Milfrod-Ward, A. 339,  
     353, 455  
 Miller, L.L. 461  
 Mills, R.J. 409  
 Minchin-Clarke, H.G.333  
 Mondorf, A.W. 575  
 Morell, A. 415  
 Mouray, H. 139  
 Muszynska, G. 633  
  
 Nakamura, S. 645  
 Nakayama, H. 645  
 Neame, P.J. 513  
 Nevin, N.C. 367  
 Nishi, S. 303  
 Noller, E. 437  
  
 Ockhuizen, Th. 421  
 Oda, T. 427  
 Ohlsson, K. 44  
 Oravisto, K.J. 589  
  
 Pace, M. 623  
 Page, M. 565  
 Pahud, J.J. 571  
 Pannell, R. 109  
 Peanasky, R. 279  
 Peeters, H. 681  
 Pennewiss, H. 505  
 Perrella, M. 623  
 Petersen, T.E. 145  
 Pierce, J.A. 249  
 Pietta, P.G. 623  
 Plainer, H. 505  
 Pondman, K.W. 69  
 Porath, J. 517  
 Probst, M. 415  
  
 Quast, U. 57  
  
 Radl, J. 405  
 Ramlau, J. 73  
 Rapic, N. 481  
 Regoeczi, E. 475, 545  
 Ribich, W.N. 471  
 Ritchie, R.F. 317  
 Robert, L. 206  
 Roberts, H.R. 145  
 Roeder, A.H. 639  
 Ropartz, C. 245 371  
 Rosengren, J. 531  
 Rytömaa, T. 589  
  
 Saklatvala, J. 99, 129  
 Sampson, P. 119  
 Sarna, S. 589  
 Scharpé, S. 79, 627  
 Scherberich, J.E. 575  
 Schiessler, H. 163  
 Schliep, G. 481  
 Schmidt, J.W. 581  
 Schorn, K. 231  
 Schrode, J. 235  
 Schwick, H.G. 309  
 Sesboue, R. 245, 371  
 Setchell, B.P. 171  
 Sieber, A. 295  
 Skavril, F. 415  
 Soble, L.W. 217, 221  
 Sorgente, N. 217, 221,  
     227  
 Sottrup-Jensen, L. 145  
 Spencer, R. 551  
 Stabilini, R. 451  
 Steinbuch, M. 115, 133  
 Stewart, C.R. 363  
 Strandström, H. 589  
 Suddath, F.L. 551  
 Suh, J. 27  
 Sundberg, L. 517  
 Suominen, J.J.O. 171  
 Swannell, A.J. 465  
  
 Tallberg, Th. 589  
 Takeo, K. 645  
 Tamboer, W.P.M. 609  
 Tanaka, N. 427  
 Tschesche, H. 57, 202,  
     271, 255  
 Travis, J. 35, 109  
 Turunen, M. 589  
 Tykkä, H. 589  
  
 Van der Loo, W. 603  
 Van Kamp, G.J. 609  
 Van Royen, E.A. 69  
  
 Voss, M. 69  
  
 Wachter, E. 267  
 Wagner, G. 189, 202  
 Waldmann-Meyer, H. 691  
 Wallner, O. 177  
 Ward, P.H. 541  
 Watkins, J. 353, 455  
 White, D.D. 129  
 White, P.A.E. 455  
 Wibell, L. 343  
 Wijdeveld, P.G.A.B. 609  
 Wilson, K.A. 235  
 Winckler, K. 195  
 Wong, K.L. 475  
 Wood, G.C. 99, 129  
 Wood, S.M. 349  
 Wormsley, K.G. 195  
 Wright, C.L. 541  
 Wunderer, G. 285  
 Wüthrich, K. 189, 202

S U B J E C T I N D E X

- Affinity chromatography 504 - 699  
 automation 603, 609  
 large-scale 603  
 ligand  
   adenosine 5 monophosphate 513  
   arsalinic acid 623  
   concanavalin A 565, 575  
   ferritin 571  
   glycocholic acid 617  
   heparin 545, 581  
   immunoglobulin 559  
   organic compound 531  
   lysine 545  
 matrix 495, 513, 531  
   acrylamide bead 50,  
   agarose 517, 581, 639, 681  
   Sephacrose 359, 495, 513, 525,  
     531, 551, 559, 565, 571,  
     575, 609, 613, 617, 623,  
     633, 651, 663, 671, 681,  
     687  
   trypsin-resin 255, 517  
   substitution 517, 531, 687  
   activation 517, 525  
 Albumin 295, 299, 435, 451, 455,  
 537, 681  
 Alpha-antitrypsin 44, 48, 79, 85,  
 119, 125, 151, 157, 163, 245, 249,  
 359, 371, 373, 377, 385, 445, 455,  
 phenotyping 373, 377, 385, 393,  
 397  
 deficiency 377, 385, 389, 393,  
 397  
 Alpha-fetoprotein 3, 313, 353, 565  
 Amino acid  
   composition 255  
   sequence 35, 184  
   sulphydryl group 35, 537  
 Animal  
   ascaris lumbricoides 279  
   baboon 245, 249  
   boar 255  
   bovine 93, 99, 202, 211, 235,  
     571, 623  
   guinea-pig 255, 571  
   monkey 249  
   mouse 405, 609  
   pig 235  
   rabbit 63, 405, 645  
   rat 195, 471, 481  
   snail 202, 271  
 Antibody - antigen 313, 589, 599, 603  
 609  
 Bacteria 617  
 Carcino-embryonic antigen 3, 313, 565  
 Catalysis 505  
 Cell  
   blastocyst 63  
   endothelial cell 221  
   erythrocyte 73  
   fibroblast 217, 221  
   leucocyte 205  
   platelet 205  
   reticulo endothelial cell 44, 589  
 Cerebrospinal fluid 491, 499  
 Cervical mucus 177  
 Chromatography 48, 609, 691  
   affinity : see Affinity chromato-  
     graphy  
   cellulose 267, 651  
   covalent 537  
   hydrophobic : see Hydrophobic  
   chromatography  
   porous glass 691  
   Sephadex 227  
 Circular dichroism 129  
 Clinical diagnosis 319, 327, 335  
 Colostrum 571  
 Complement 69, 359, 397, 451, 455, 551  
 Cord Serum 373  
 Disease  
   Bence-Jones proteinemia 359, 405,  
     431  
   immune system disorders 405, 415,  
     431, 441  
   liver disease 3, 119, 249, 315,  
     333, 373, 393, 397, 441, 451,  
     581  
   multiple sclerosis 333, 499  
   myelomatosis 343, 409, 431  
   nephrotic syndrome 439, 445  
   paraproteinemia 405, 409  
   rheumatoid arthritis 33, 455, 461

- pulmonary disease 109, 249, 371, 375, 377, 385  
 transplantation 343  
 tuberculosis 333  
 tumour 3, 313, 565, 589  
 Dye-binding 437
- Electrophoresis**  
 affinity electrophoresis 645  
 cellulose acetate 48  
 crossed electrophoresis 39, 245, 393  
 electrofocusing 125, 565  
 immuno- 73, 115, 125, 385, 481, 485  
 SDS-Polyacrylamide 35, 39, 439, 485  
 starch 115, 125, 133, 245, 393
- Enzyme**  
 alkaline phosphatase 3, 623  
 amylase 547, 645  
 arginase 633  
 brunase 48  
 carboxypeptidase A 27  
 carcino-fetal enzyme 3  
 chymotrypsin 44, 53, 93, 99, 129, 139, 227, 267, 547  
 dehydrogenase 513, 639  
 elastase 44, 157, 205  
 histidine decarboxylase 667  
 pepsin 541  
 phosphorylase 645, 671  
 plasmin 73, 133, 151  
 renin 79  
 stem bromelain 627  
 trypsin 44, 53, 93, 99, 119, 139, 227, 267, 445, 517  
 urokinase 39  
 inhibitor interaction : see proteinase inhibitors  
 ion binding 27  
 substrate 27, 633
- Hydrophobic chromatography** 667, 671, 681, 687
- Hormone**  
 corticosterone 471  
 androsterone 617  
 epi-androsterone 617
- Immunoglobulin** 295, 359, 405, 431, 455, 499, 559, 603  
 IgA 291  
 IgE 409  
 IgG 291, 499, 551, 609  
 IgM 291, 599  
 light chain 415
- Immunoprecipitation** 3, 291, 295, 299, 313, 339, 415, 439, 455  
 automation 291, 295, 299  
**Immunosorbent** 589, 599, 603, 609  
 enzyme-linked 613  
**Immunotherapy** 587
- Lipoproteins** 33, 437, 581, 681
- Matrix** : see Affinity chromatography  
**Membrane proteins** 73, 575, 667  
**Mercaptalbumin** 537
- Nephelometry** 291, 299  
 laser 295  
**NMR analysis** 189, 202, 531
- Pi-system** : see Alpha-antitrypsin  
**Plasma** 291, 445  
**Pregnancy** 39, 63, 177, 313, 343, 353, 359
- Proteins**  
 - acute-phase reactant proteins 461, 471  
 albumin 295, 299, 439, 451, 455, 537, 681  
 alpha-fetoprotein 3, 313, 353, 565  
 alpha-2-macroglobulin 48, 133, 139, 151, 333, 485  
 alpha-1-glycoprotein 33, 151, 559, 575  
 beta-2-macroglobulin 343  
 CEA 3, 565  
 ceruloplasmin 333, 455  
 complement : see Complement  
 glycogen 645  
 haptoglobin 333, 359  
 hemoglobin 687  
 immunoglobulin : see Immunoglobulin  
 isoferritin 3  
 lactoferrin 571  
 lipoprotein 33, 437, 581, 681  
 membrane proteins 73, 575, 667  
 mercaptalbumin 537  
 myoglobin 687  
 plasminogen 545  
 trace proteins 319  
 transferrin 299, 333, 681  
 - insolubilization 599  
 - permeability 491  
 - profile 291, 295, 299, 319, 327, 333, 335, 339, 353, 359, 405, 441, 451, 455  
 - purification 319, 599, 603  
 - quantitation 333

- Proteinase inhibitors  
  albumin gland inhibitor 271  
  alpha-antitrypsin (see Alpha-anti-  
  trypsin)  
  alpha-2-macroglobulin 48, 133,  
  139, 151, 333, 485  
  alpha-1-proteinase inhibitor 35,  
  99, 109, 217, 221  
  alpha-2-antithrombin 145, 339  
  acrosin inhibitor 163, 171, 177,  
  255  
  carboxypeptidase inhibitor 279  
  CI-esterase inhibitor 69, 151  
  hirudin 145  
  inter-alpha-inhibitor 79, 115  
  Kunitz inhibitor 53, 211  
  pancreatic basic trypsin inhibitor  
  184, 189, 195, 235, 285  
  soybean inhibitor 235  
  trypsin-kallikrein inhibitor 57, 285  
- enzyme association 39, 53, 57, 85, 93, 99,  
  129, 133, 139, 267
- Radioactivity 471, 481, 485  
Reaction kinetics 57, 85, 99  
RIA 3, 79, 211, 313, 353, 371  
RNA 651
- Saliva 267  
Sea anemones 285  
Seminal plasma 171, 255  
Sputum 389  
Sugar  
  monosaccharide 255  
  sialic acid 109, 119
- Tissue  
  aorta 205, 221, 227  
  cartilage 217, 227  
  connective tissue 217, 227  
  intestine 359, 565, 623  
  kidney 359, 575  
  liver 437, 471, 481, 565  
  muscle 671  
  pancreas 195, 205, 211  
  uterus 63  
Transferrin 299, 333, 681  
Trypsin : see Enzyme
- Urine 445
- Virus 663
- Yeast  
  candida albicans 613  
  catalase 687